PBI7 Cost-Effectiveness Analysis of Adalimumab Biosimilar Compared to Delayed Biologic Treatment Initiation in Patients with Rheumatoid Arthritis in Germany
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.078
https://www.valueinhealthjournal.com/article/S1098-3015(21)00295-3/fulltext
Title :
PBI7 Cost-Effectiveness Analysis of Adalimumab Biosimilar Compared to Delayed Biologic Treatment Initiation in Patients with Rheumatoid Arthritis in Germany
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00295-3&doi=10.1016/j.jval.2021.04.078
First page :
Section Title :
Open access? :
No
Section Order :
10251